REVIVA PHARMACEUTICALS HOLDINGS, INC. short interest in 2022
In 2022, REVIVA PHARMACEUTICALS HOLDINGS, INC.'s disclosed short interest ran from 1.11% of shares outstanding on 14 Jan 2022 to 4.71% on 30 Dec 2022, a change of +3.60 percentage points. The year's high was 5.99% on 15 Nov 2022 and its low 0.26% on 15 Mar 2022, averaging 2.45% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.91 days on 15 Jul 2022. Full history: REVIVA PHARMACEUTICALS HOLDINGS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 1.11% (14 Jan 2022)
- End of year
- 4.71% (30 Dec 2022)
- Change
- +3.60 pp
- High
- 5.99% (15 Nov 2022)
- Low
- 0.26% (15 Mar 2022)
- Average
- 2.45%
- Highest days to cover
- 6.91 (15 Jul 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.11% | 1.00 | |
| 31 Jan 2022 | 0.94% | 1.00 | |
| 15 Feb 2022 | 1.00% | 1.47 | |
| 28 Feb 2022 | 0.81% | 1.12 | |
| 15 Mar 2022 | 0.26% | 1.00 | 10-K filed, results (8-K) |
| 13 May 2022 | 0.31% | 1.00 | |
| 31 May 2022 | 0.72% | 2.49 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 0.89% | 2.73 | |
| 30 Jun 2022 | 1.87% | 3.91 | |
| 15 Jul 2022 | 3.32% | 6.91 | |
| 29 Jul 2022 | 5.91% | 1.59 | |
| 15 Aug 2022 | 1.38% | 1.00 | 10-Q filed, results (8-K) |
| 15 Nov 2022 | 5.99% | 1.74 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 5.02% | 3.55 | |
| 15 Dec 2022 | 5.03% | 4.90 | |
| 30 Dec 2022 | 4.71% | 3.52 |
See also: REVIVA PHARMACEUTICALS HOLDINGS, INC.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.